CCCC: Targeted Protein Degradation (TPD) – Master Valuation File
A 20-year risk-adjusted horizon analysis of C4 Therapeutics. Solving for liquidity constraints, rNPV of lead candidate CFT7455, and the mechanics of binary price discovery.
01_FUNDAMENTAL_PHILOSOPHY: BEYOND THE NOISE
To begin at the beginning: we must demystify “fundamentals.” Reading an economic calendar or recalculating standard ratios offers zero “extra” information compared to the market. On high-cap stocks, information pricing is highly efficient.
The Alpha: Value is found in T+1. We look for the realization of new value in pre-commercial biotechs where the “Invisible Hand” is less precise. Inefficiency—and therefore opportunity—appears when the market unfairly devalues an asset whose fundamental catalysts haven’t moved. We aren’t trading charts; we are trading the resolution of clinical uncertainty.
02_PLATFORM_DYNAMICS: THE TPD ENGINE
C4 Therapeutics is a clinical-stage pioneer in Targeted Protein Degradation (TPD). Unlike traditional inhibitors that merely block a protein’s function, C4’s platform recruits the cell’s endogenous E3 ubiquitin ligase to tag and destroy disease-causing proteins.
Technical Differentiation:
- Catalytic Recycling: A single C4 molecule can trigger the destruction of multiple proteins, allowing for sub-stoichiometric dosing.
- Overcoming Resistance: By eliminating the protein entirely, C4 bypasses the binding-site mutations that render traditional Kinase inhibitors useless.
- Targeted Indication: Lead candidate CFT7455 (cemsidomide) targets Multiple Myeloma and Peripheral T-cell Lymphoma (5th line+).
03_FINANCIAL_ARCHITECTURE: THE LIQUIDITY BACKSOLVE
A biotech’s only activity is burning cash to buy data. Our 3-statement model “backsolves” cash liquidation to find the true “Zero-Cash Date.”
Quarterly Cash Burn & Runway (Model Output):
| Metric (in $000s) | Q1 2024 (A) | Q4 2024 (E) | Q4 2025 (E) | Q4 2027 (Target) |
|---|---|---|---|---|
| Revenue | 3,039 | 5,177 | 9,342 | 9,982 |
| R&D Expense | 22,533 | 32,513 | 29,818 | 35,311 |
| Net Income | (28,361) | (34,573) | (25,927) | (30,640) |
| Cash & Equiv. | 89,659 | 55,497 | 38,300 | 676 |
Conclusion: At a negative quarterly cash flow of >$4M, the company has sufficient liquidity to finance operations until Q4 2027, aligning with corporate guidance.
04_REVENUE_MODULES: COLLABORATION MILESTONES
C4’s revenue isn’t commercial yet—it’s collaborative. We have modeled five major partnerships with a total milestone potential of $2.49 Billion.
Milestone Allocation Schedule:
| Partner | Total Potential | Allocation Method | Remaining SK |
|---|---|---|---|
| MKDG | $740.0M | Back Loaded Exponential | $724.0M |
| Merck | $600.0M | Back Loaded Exponential | $590.0M |
| Roche | $423.0M | Linear | $383.0M |
| Betta Pharma | $357.0M | Bell Shaped | $347.0M |
| Biogen | $375.0M | Back Loaded Exponential | $330.0M |
These milestones are heavily weighted toward Phase 3 and NDA filings (approx. 30% each), creating a “Value Cliff” in the early 2030s.
05_COMMERCIAL_MODELING: THE CFT7455 “PALACE”
The goal is to ensure the “palace” at the end of the road is bigger than the “bricks” (cash) we used to build it.
Epidemiology & Market Sizing:
Using SEER, Globocan, and NIH data, we project revenue for cemsidomide based on 5th-line Multiple Myeloma populations.
- Projected Market Entry: 2035 (Based on IQVIA oncology phase durations: P1=2.7y, P2=3.3y, P3=3.1y).
- Peak Revenue (2045): ~$2.0 Billion.
06_THE_MATHEMATICS_OF_VALUE: rNPV & DOUBLE DISCOUNTING
A $2B revenue stream in 2045 is a mirage without risk adjustment. We apply a “Double Discount” to reach a fair value.
- Time Value of Money (TVM): 20 years of discounting at a 15% WACC.
- Clinical Risk: We apply cumulative Probability of Success (PoS) for Immuno-Oncology.
The Math of Reality:
- Raw 2045 Revenue: $2,000,000,000
- Risk Adjustment: 12.41% (Cumulative PoS for P1 candidate)
- Discounted rNPV: ~$12,000,000 total today.
- Intrinsic Share Value: Currently modeled at $3.34/share.
07_BINARY_EVENTS: THE MECHANICS OF PRICE DISCOVERY
Why the massive gaps in price? Clinical results are discrete binary events that instantly reset the “Risk Adjustment” factor in the rNPV equation.
Value Jump Mechanics:
- Phase 1 Success: The Cumulative PoS jumps from 12.4% → 19.4%. The rNPV/share instantly adjusts to $5.22 (+56%).
- Phase 2 Success: This is the “Valley of Death” with the highest failure rate. Passing P2 removes the largest penalty, jumping value to $12.98 (+148%).
This is what “The Market” observes. The price doesn’t move because of “order flow”—it moves because sophisticated actors have recalculated the fundamental floor.